Институт стволовых клеток человека ISKJ

Институт стволовых клеток человека Kennzahlen 2006-2025 | ISKJ

Kennzahlen Jährlich Институт стволовых клеток человека

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006
Price Earnings Ratio, P/E	42.36	145.3	274.0	27.68	11.52	-17.45	-8.41	-12.16	-15.21	-62.53	99.14	-6.8	45.37	114.89	19.64	131.64	144.8	-
Price Sales Ratio, P/S	5.23	5.89	7.78	2.64	1.17	0.93	1.74	3.47	2.52	2.3	3.48	3.22	3.17	4.01	5.94	9.17	13.62	-
Price To Book Ratio, P/B	14.29	19.65	39.15	14.73	9.87	22.09	16.84	8.8	2.72	2.43	4.15	1.55	1.03	4.0	4.49	56.18	71.8	-
Price Earnings To Growth Ratio, PEG	0.17	5.55	-3.94	1.25	-0.03	0.26	1.13	-0.11	-0.05	0.33	-0.9	0.04	0.02	-1.33	0.03	13.16	-	-
Operating Cash Flow Per Share	4.69	2.53	3.51	0.72	2.34	0.26	-0.26	0.48	0.06	0.51	1.1	-0.35	0.59	0.0	0.73	0.5	0.08	-
Free Cash Flow Per Share	2.48	0.97	1.59	-0.42	-0.27	-0.21	-3.1	-0.41	-0.2	0.07	0.64	-1.02	0.16	-0.14	0.55	0.19	-0.04	-
Cash Per Share	6.17	3.25	2.73	1.7	2.54	2.73	1.72	5.04	2.8	2.77	1.47	0.36	0.24	1.17	2.57	0.07	0.09	-
Payout Ratio	-	-	-	-	-	-	-	-0.19	-	-	-	-	-	1.12	0.19	0.5	-	-
Dividend Yield	-	-	-	-	-	-	-	0.02	-	-	-	-	-	0.01	0.01	0.0	-	-
Current Ratio	1.99	1.74	1.77	1.04	1.05	1.15	0.71	1.18	0.86	0.89	0.66	0.82	1.02	1.47	2.41	0.41	1.0	0.95
Quick Ratio	1.59	1.18	1.11	0.62	0.69	0.81	0.48	1.04	0.74	0.76	0.62	0.73	0.88	1.38	2.36	0.35	0.91	0.87
Cash Ratio	0.97	0.51	0.52	0.19	0.18	0.16	0.19	0.6	0.12	0.19	0.06	0.13	0.17	0.7	2.0	0.09	0.23	0.12
Days Of Sales Outstanding, DSO	21.82	-	-	-	-	-	-	-	-	-	-	29.43	-	-	-	-	-	-
Days Of Inventory Outstanding, DIO	205.28	314.65	309.57	274.8	383.57	632.62	489.26	348.28	400.96	630.98	334.6	187.13	188.64	1451.81	270.24	537.47	1887.45	-
Days Of Payables Outstanding, DPO	48.44	93.94	128.87	114.55	183.58	557.57	287.45	475.79	148.59	115.17	358.41	166.17	347.4	942.75	819.86	8023.06	19236.82	-
Operating Cycle	227.1	314.65	309.57	274.8	383.57	632.62	489.26	348.28	400.96	630.98	334.6	216.56	188.64	1451.81	270.24	537.47	1887.45	-
Cash Conversion Cycle	178.66	220.71	180.69	160.24	199.99	75.05	201.82	-127.5	252.37	515.81	-23.81	50.39	-158.76	509.06	-549.62	-7485.59	-17349.37	-
Gross Profit Margin	0.71	0.77	0.75	0.71	0.8	0.88	0.81	0.83	0.85	0.92	0.96	0.9	0.89	0.99	0.97	0.98	0.99	-
Operating Profit Margin	0.2	0.1	0.08	0.14	0.22	0.18	-0.12	-0.37	-0.31	-0.14	0.1	-0.04	0.06	0.04	0.19	0.06	0.11	-
Pretax Profit Margin	0.15	0.03	0.02	0.09	0.12	-0.08	-0.26	-0.38	-0.19	0.0	0.07	-0.45	0.07	0.05	0.34	0.09	0.12	-
Net Profit Margin	0.12	0.04	0.03	0.1	0.1	-0.05	-0.21	-0.29	-0.17	-0.04	0.04	-0.47	0.07	0.03	0.3	0.07	0.09	-
Effective Tax Rate	0.08	0.21	-0.14	-0.11	-0.1	0.66	0.14	0.13	-0.04	104.76	0.39	-0.05	-0.09	0.32	0.12	0.22	0.26	-
Return On Assets, ROA	0.07	0.02	0.02	0.07	0.06	-0.03	-0.1	-0.11	-0.06	-0.02	0.02	-0.15	0.02	0.02	0.16	0.1	0.17	-
Return On Equity, ROE	0.34	0.14	0.14	0.53	0.86	-1.27	-2.0	-0.72	-0.18	-0.04	0.04	-0.23	0.02	0.03	0.23	0.43	0.5	-
Return On Capital Employed, ROCE	0.14	0.07	0.07	0.15	0.2	0.16	-0.12	-0.26	-0.23	-0.12	0.11	-0.01	0.02	0.04	0.14	0.36	0.53	-
Net Income Per Ebt	0.8	1.57	1.14	1.11	0.83	0.64	0.81	0.74	0.85	-82.46	0.54	1.05	0.95	0.71	0.89	0.79	0.77	-
Ebt Per Ebit	0.77	0.26	0.32	0.64	0.56	-0.46	2.19	1.04	0.63	-0.0	0.64	12.05	1.16	1.33	1.83	1.38	1.1	-
Ebit Per Revenue	0.2	0.1	0.08	0.14	0.22	0.18	-0.12	-0.37	-0.31	-0.14	0.1	-0.04	0.06	0.04	0.19	0.06	0.11	-
Debt Ratio	0.31	0.41	0.36	0.32	0.3	0.33	0.39	0.33	0.14	0.12	0.18	0.15	0.01	0.0	0.0	0.05	-	-
Debt Equity Ratio	1.57	2.44	2.63	2.51	4.3	13.86	8.09	2.25	0.4	0.29	0.37	0.23	0.01	0.0	0.0	0.19	-	-
Long Term Debt To Capitalization	0.46	0.64	0.68	0.47	0.59	0.92	0.88	0.67	0.08	-	0.09	0.09	0.0	-	-	-	-	-
Total Debt To Capitalization	0.61	0.71	0.72	0.72	0.81	0.93	0.89	0.69	0.29	0.23	0.27	0.18	0.01	0.0	0.0	0.16	-	-
Interest Coverage	-	1.64	1.82	3.66	4.34	3.88	-1.89	-5.31	-11.05	-4.29	2.31	-2.17	40.2	23.51	76.98	28.88	183.43	-
Cash Flow To Debt Ratio	0.55	0.26	0.46	0.11	0.41	0.05	-0.05	0.1	0.04	0.39	0.64	-0.18	4.03	7.67	5492.12	10.12	-	-
Company Equity Multiplier	5.08	6.0	7.4	7.78	14.17	41.62	20.57	6.76	2.89	2.38	2.07	1.53	1.21	1.53	1.41	4.13	2.98	3.15
Receivables Turnover	16.72	-	-	-	-	-	-	-	-	-	-	12.4	-	-	-	-	-	-
Payables Turnover	7.53	3.89	2.83	3.19	1.99	0.65	1.27	0.77	2.46	3.17	1.02	2.2	1.05	0.39	0.45	0.05	0.02	-
Inventory Turn Over	1.78	1.16	1.18	1.33	0.95	0.58	0.75	1.05	0.91	0.58	1.09	1.95	1.93	0.25	1.35	0.68	0.19	-
Fixed Asset Turnover	4.33	4.05	4.14	3.28	2.2	2.33	1.75	2.55	3.22	3.25	3.57	4.78	7.08	5.38	4.38	3.7	6.26	-
Asset Turnover	0.54	0.56	0.68	0.72	0.6	0.57	0.47	0.38	0.37	0.45	0.58	0.32	0.27	0.65	0.54	1.48	1.77	-
Operating Cash Flow Sales Ratio	0.32	0.19	0.24	0.05	0.21	0.03	-0.04	0.09	0.01	0.11	0.2	-0.08	0.16	0.0	0.3	0.32	0.08	-
Free Cash Flow Operating Cash Flow Ratio	0.53	0.38	0.45	-0.59	-0.12	-0.82	11.83	-0.86	-3.2	0.14	0.58	2.89	0.28	-73.52	0.75	0.37	-0.5	-
Cash Flow Coverage Ratios	0.55	0.26	0.46	0.11	0.41	0.05	-0.05	0.1	0.04	0.39	0.64	-0.18	4.03	7.67	5492.12	10.12	-	-
Short Term Coverage Ratios	1.97	2.06	1390.1	0.3	1.27	0.38	-0.4	0.93	0.05	0.39	0.91	-0.3	4.34	7.67	5492.12	10.12	-	-
Capital Expenditure Coverage Ratio	2.13	1.62	1.83	0.63	0.9	0.55	-0.09	0.54	0.24	1.16	2.39	-0.53	1.38	0.01	4.01	1.6	0.67	-
Dividend Paid And Capex Coverage Ratio	2.13	1.62	1.83	0.63	0.9	0.55	-0.09	0.41	0.24	1.16	2.39	-0.53	1.38	0.01	2.25	1.36	0.67	-
Dividend Payout Ratio	-	-	-	-	-	-	-	-0.19	-	-	-	-	-	1.12	0.19	0.5	-	-
Price To Free Cash Flows Ratio, P/FCF	31.03	79.42	72.09	-90.18	-47.45	-37.51	-3.71	-43.83	-53.32	153.57	30.4	-13.26	71.12	-91.33	26.39	77.5	-357.13	-
Price To Operating Cash Flows Ratio, P/OCF	16.45	30.42	32.73	53.13	5.55	30.74	-43.9	37.55	170.38	21.58	17.69	-38.3	19.71	6714.78	19.81	29.06	177.07	-
Price Cash Flow Ratio, P/CF	16.45	30.42	32.73	53.13	5.55	30.74	-43.9	37.55	170.38	21.58	17.69	-38.3	19.71	6714.78	19.81	29.06	177.07	-
Enterprise Value Multiple, EV	22.69	48.68	59.57	15.55	6.45	7.09	-431.98	-14.34	-14.4	22.99	24.41	105.48	32.0	44.55	13.32	80.54	99.64	-
Price Fair Value, P/FV	14.29	19.65	39.15	14.73	9.87	22.09	16.84	8.8	2.72	2.43	4.15	1.55	1.03	4.0	4.49	56.18	71.8	-

Alle Zahlen in RUB-Währung

Kennzahlen Vierteljährlich Институт стволовых клеток человека

	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q3
Price Earnings Ratio, P/E	34.3 K	34.3 K	21.2 K	21.2 K	89.8 K	89.8 K	162 K	162 K	133 K	154 K	196	-484 K	24.9	71.1 K	24.8	3.07 M	40.9	6.05 K	0.003	16.8 K	6.54 K	6.76 K	-4.43 K	-5.12 K	10.7 K	10.2 K	-2.59	9.9	-9.21 K	-13.6 K	-53.8	-8.22	-	-68.5	-5.77 K	-5.66 K	21.4 K	21.3 K	-8.85 K	-9.84 K	15.9 K	5.34	-28 K	-25.7 K	-	12.3	-
Price Sales Ratio, P/S	15.3 K	15.3 K	15.5 K	15.5 K	18.4 K	18.4 K	22.2 K	22.2 K	25.6 K	29.6 K	13.5	25.1 K	5.01	10.1 K	4.99	8.13 K	2.98	3.87 K	0.002	4.94 K	3.49 K	3.6 K	3.4 K	3.93 K	4.86 K	4.63 K	6.07	7.84	8.04	9.39	12.9	16.6	-	21.3	9.87	9.68	9.23 K	9.18 K	8.91	9.91	12.2 K	10.9	14.3 K	13.2 K	-	8.59	-
Price To Book Ratio, P/B	13.2 K	13.2 K	11.6 K	11.6 K	15 K	15 K	20.1 K	20.1 K	24.1 K	27.8 K	35.9 K	33.3 K	12.5 K	12.6 K	14.3 K	13.2 K	8.7 K	4.05 K	9.87	10 K	4.37 K	4.52 K	22.1 K	25.5 K	6.13 K	5.84 K	16.8	7.31	8.22 K	8.06 K	8.8	8.57	-	7.1	2.72 K	2.67 K	1.97 K	1.96 K	2.43 K	2.7 K	2.38 K	1.43	4.15 K	1.7 K	-	1.41	-
Price Earnings To Growth Ratio, PEG	-	-1.03 K	-	60.5	-	898	-	-	-	-1.54 K	-	4.84 K	0.0	-711	-	-30.7 K	0.001	-60.5	0.0	-503	-	-38.6	-	17.1	-	-102	0.006	-0.0	-	136	0.633	0.325	-	-0.004	-	9.43	-	-160	-	39.4	-159	-0.0	-	-	-	-	-
Operating Cash Flow Per Share	0.001	0.001	0.003	0.003	0.0	0.0	0.001	0.001	0.0	0.0	2.71	0.001	0.51	0.0	-	0.001	-	-0.0	-	0.001	0.0	0.0	-0.0	-0.0	0.001	0.001	0.54	-0.173	-0.0	-0.0	1.88	-1.11	-	-0.316	0.0	0.0	-0.0	-0.0	-0.0	-	0.0	-	0.0	-	-	-	-
Free Cash Flow Per Share	0.0	0.0	0.002	0.002	-0.0	-0.0	0.001	0.001	-0.0	-0.0	0.763	0.001	-0.225	-0.0	-	0.001	-	-0.001	-	-0.0	0.0	0.0	-0.0	-0.0	-0.0	-0.0	0.323	-0.854	-0.002	-0.001	1.2	-1.2	-	-0.316	0.0	0.0	-0.0	-0.0	-0.0	-	0.0	-	0.0	-	-	-	-
Cash Per Share	0.005	0.005	0.008	0.008	0.005	0.005	0.003	0.003	0.001	0.001	0.003	0.002	0.001	0.001	0.002	0.001	0.003	0.002	2.54	0.002	0.002	0.002	0.003	0.003	0.003	0.003	1.72	2.66	0.004	0.006	5.04	4.75	-	2.39	0.003	0.003	0.003	0.002	0.002	0.002	0.003	2.62	0.001	0.001	-	1.16	-
Payout Ratio	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Dividend Yield	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.88	1.88	1.99	1.99	2.09	2.09	1.74	1.74	1.98	1.98	1.77	1.77	1.32	1.32	1.04	1.04	1.41	1.41	1.05	1.05	1.22	1.22	1.15	1.15	0.804	0.804	0.705	0.934	0.946	1.27	1.18	1.28	0.699	0.697	0.863	0.863	0.953	0.953	0.895	0.895	0.939	0.852	0.662	0.783	1.05	0.826	0.895
Quick Ratio	1.41	1.41	1.59	1.59	1.61	1.61	1.18	1.18	1.21	1.21	1.11	1.11	0.689	0.689	0.616	0.616	0.829	0.829	0.691	0.691	0.848	0.848	0.814	0.814	0.624	0.624	0.483	0.775	0.808	1.14	1.04	1.17	0.55	0.697	0.738	0.738	0.802	0.802	0.756	0.756	0.895	0.817	0.616	0.727	0.923	0.768	0.831
Cash Ratio	0.686	0.686	0.971	0.971	0.796	0.796	0.51	0.51	0.202	0.202	0.519	0.519	0.12	0.12	0.193	0.193	0.344	0.344	0.184	0.184	0.143	0.143	0.156	0.156	0.135	0.135	0.191	0.235	0.367	0.668	0.598	0.694	0.053	0.069	0.121	0.121	0.161	0.161	0.194	0.194	0.276	0.142	0.056	0.02	0.224	0.016	0.088
Days Of Sales Outstanding, DSO	20.8	20.8	19.7	19.7	-	30.1	-	19.8	-	23	0.012	24	0.016	31.6	-	25.7	-	21.5	-	24.7	-	23	-	22.4	-	30.4	-	-	-	0.053	-	34.6	-	-	-	0.027	-	30.7	0.018	0.018	-	-	49.2	-	-	-	-
Days Of Inventory Outstanding, DIO	244	244	171	171	239	239	153	153	212	212	0.05	184	0.056	206	0.052	130	0.051	731	0.061	250	352	352	476	476	265	265	279	520	198	142	291	170	131	-	129	129	207	207	182	182	74.2	15.3	101	107	-	34.3	-
Days Of Payables Outstanding, DPO	27.1	27.1	40.4	40.4	161	36	45.5	23.1	104	51	0.021	27	0.02	73	0.022	19.7	0.02	87.2	0.029	59.3	168	168	419	276	215	179	164	408	291	188	397	124	110	128	47.6	38	40.7	20.4	14.2	14.2	92.8	315	40.2	1.29 K	-	384	-
Operating Cycle	264	264	191	191	239	269	153	172	212	235	0.062	208	0.072	238	0.052	156	0.051	753	0.061	274	352	375	476	498	265	296	279	520	198	142	291	205	131	-	129	129	207	238	182	182	74.2	15.3	150	107	-	34.3	-
Cash Conversion Cycle	237	237	150	150	78.3	233	107	149	109	184	0.041	181	0.052	165	0.03	136	0.031	665	0.032	215	184	207	56.4	223	50.5	117	115	112	-92.6	-45.8	-106	80.5	21.4	-128	80.9	90.6	167	218	168	168	-18.6	-299	110	-1.18 K	-	-349	-
Gross Profit Margin	0.75	0.75	0.681	0.681	0.736	0.736	0.572	0.572	0.629	0.629	0.296	0.616	0.274	0.602	0.274	0.489	0.244	0.854	0.435	0.724	0.797	0.797	0.852	0.852	0.756	0.756	0.719	0.899	1.0	1.0	0.811	0.731	0.606	0.865	1.0	1.0	0.688	0.688	1.0	1.0	0.796	0.331	0.868	0.868	-	0.647	-
Operating Profit Margin	0.223	0.223	0.228	0.228	0.169	0.169	0.077	0.077	0.122	0.122	0.044	0.086	0.078	0.118	0.093	0.096	0.075	0.303	0.213	0.239	0.189	0.189	0.343	0.343	-0.011	-0.011	-0.043	0.03	-0.0	-0.0	-0.37	-0.755	-0.425	0.041	-0.0	-0.0	-0.121	-0.121	-0.0	-0.0	-0.082	0.031	0.002	0.002	-	0.426	-
Pretax Profit Margin	0.136	0.136	0.225	0.225	0.07	0.07	-0.0	-0.0	0.057	0.057	0.018	0.013	0.043	0.039	0.043	0.02	0.021	0.178	0.178	0.083	0.166	0.166	-0.231	-0.231	0.093	0.093	-0.595	0.124	-0.0	-0.0	-0.176	-0.73	-0.575	-0.088	-0.0	-0.0	0.116	0.116	-0.0	-0.0	0.24	0.668	-0.115	-0.115	-	0.228	-
Net Profit Margin	0.112	0.112	0.183	0.183	0.051	0.051	0.034	0.034	0.048	0.048	0.017	-0.013	0.05	0.035	0.05	0.001	0.018	0.16	0.204	0.074	0.133	0.133	-0.192	-0.192	0.113	0.113	-0.585	0.198	-0.0	-0.0	-0.06	-0.506	-0.514	-0.078	-0.0	-0.0	0.108	0.108	-0.0	-0.0	0.192	0.511	-0.128	-0.128	-	0.175	-
Effective Tax Rate	0.022	0.022	0.056	0.056	0.17	0.17	-55.1	-55.1	0.017	0.017	0.018	0.025	-0.181	199	-0.181	0.139	0.135	146	-0.146	292	0.017	0.017	-0.359	-0.359	235	235	0.067	-0.625	-0.075	-0.01	0.339	0.197	-0.006	0.121	-0.02	-0.02	0.214	0.214	-0.12	-0.12	0.282	0.235	-0.174	-0.174	-	0.233	-
Return On Assets, ROA	0.017	0.017	0.027	0.027	0.007	0.007	0.005	0.005	0.007	0.007	6.2	-0.002	18.7	0.007	18.5	0.0	7.24	0.023	66	0.012	0.018	0.018	-0.03	-0.03	0.015	0.015	-0.079	0.024	-0.023	-0.018	-0.006	-0.042	-0.074	-0.009	-0.041	-0.041	0.01	0.01	-0.029	-0.029	0.02	0.045	-0.018	-0.012	-	0.02	-
Return On Equity, ROE	0.096	0.096	0.137	0.137	0.042	0.042	0.031	0.031	0.045	0.045	45.9	-0.017	125	0.044	144	0.001	53.2	0.168	934	0.15	0.167	0.167	-1.25	-1.25	0.143	0.143	-1.62	0.185	-0.223	-0.148	-0.041	-0.261	-0.278	-0.026	-0.118	-0.118	0.023	0.023	-0.069	-0.069	0.037	0.067	-0.037	-0.017	-	0.029	-
Return On Capital Employed, ROCE	0.042	0.042	0.043	0.043	0.028	0.028	0.014	0.014	0.022	0.022	20.3	0.02	39.6	0.03	54.1	0.032	41.9	0.061	106	0.059	0.036	0.036	0.085	0.085	-0.003	-0.003	-0.012	0.006	-0.033	-0.059	-0.069	-0.108	-0.138	0.01	-0.093	-0.093	-0.019	-0.019	-0.042	-0.042	-0.014	0.004	0.0	0.0	-	0.064	-
Net Income Per Ebt	0.82	0.82	0.816	0.816	0.734	0.734	-173	-173	0.85	0.85	0.982	-1.02	1.18	0.914	1.18	0.032	0.865	0.899	1.15	0.885	0.803	0.803	0.83	0.83	1.21	1.21	0.983	1.6	0.846	0.68	0.34	0.693	0.893	0.879	0.871	0.871	0.928	0.928	1.12	1.12	0.8	0.765	1.11	1.11	-	0.767	-
Ebt Per Ebit	0.609	0.609	0.984	0.984	0.415	0.415	-0.003	-0.003	0.463	0.463	0.395	0.148	0.545	0.328	0.458	0.213	0.281	0.587	0.833	0.349	0.877	0.877	-0.674	-0.674	-8.84	-8.84	13.9	4.18	1.51	0.797	0.475	0.966	1.35	-2.13	1.01	1.01	-0.96	-0.96	1.12	1.12	-2.93	21.4	-74.9	-74.9	-	0.535	-
Ebit Per Revenue	0.223	0.223	0.228	0.228	0.169	0.169	0.077	0.077	0.122	0.122	0.044	0.086	0.078	0.118	0.093	0.096	0.075	0.303	0.213	0.239	0.189	0.189	0.343	0.343	-0.011	-0.011	-0.043	0.03	-0.0	-0.0	-0.37	-0.755	-0.425	0.041	-0.0	-0.0	-0.121	-0.121	-0.0	-0.0	-0.082	0.031	0.002	0.002	-	0.426	-
Debt Ratio	0.315	0.315	0.309	0.309	0.345	0.345	0.407	0.407	0.356	0.356	0.355	0.355	0.318	0.318	0.323	0.323	0.329	0.329	0.303	0.303	0.364	0.364	0.333	0.333	0.36	0.36	0.393	0.403	0.4	0.393	0.333	0.396	0.099	0.142	0.138	0.138	0.139	0.139	0.123	0.123	0.161	0.098	0.177	0.121	0.124	0.143	0.111
Debt Equity Ratio	1.82	1.82	1.57	1.57	2.13	2.13	2.44	2.44	2.25	2.25	2.63	2.63	2.14	2.14	2.51	2.51	2.41	2.41	4.3	3.83	3.38	3.38	13.9	13.9	3.47	3.47	8.09	3.13	3.94	3.28	2.25	2.43	0.368	0.413	0.399	0.399	0.329	0.329	0.292	0.292	0.3	0.146	0.367	0.172	0.175	0.21	0.156
Long Term Debt To Capitalization	0.503	0.503	0.461	0.461	0.606	0.606	0.638	0.638	0.647	0.647	0.678	0.678	0.473	0.473	0.474	0.474	0.496	0.496	0.593	0.564	0.69	0.69	0.923	0.923	0.744	0.744	0.876	0.737	0.781	0.746	0.667	0.66	0.067	0.063	0.079	0.079	0.067	0.067	-	-	0.055	0.043	0.095	0.055	0.063	0.082	0.051
Total Debt To Capitalization	0.646	0.646	0.611	0.611	0.68	0.68	0.709	0.709	0.693	0.693	0.724	0.724	0.681	0.681	0.715	0.715	0.707	0.707	0.811	0.793	0.772	0.772	0.933	0.933	0.777	0.777	0.89	0.758	0.798	0.766	0.692	0.709	0.269	0.292	0.285	0.285	0.248	0.248	0.226	0.226	0.231	0.127	0.268	0.147	0.149	0.173	0.135
Interest Coverage	-	-	-	-	-	-	-	-	-	-	0.779	-	1.55	-	1.84	-	1.39	-	5.97	-	-	-	-	-	-	-	-0.727	0.461	-	-	-2.33	-21.9	-11.9	1.07	-	-	-	-	-	-	-	0.871	-	-	-	11.4	-
Cash Flow To Debt Ratio	0.072	0.072	0.243	0.243	0.032	0.032	0.104	0.104	0.038	0.038	323	0.184	77.8	0.056	-	0.127	-	-0.067	-	0.18	0.029	0.029	-0.082	-0.082	0.1	0.1	0.098	-0.031	-0.046	-0.062	0.407	-0.213	0.024	-0.204	0.216	0.216	-0.192	-0.192	-0.142	-	0.247	-	0.058	-	-	-	-
Company Equity Multiplier	5.8	5.8	5.08	5.08	6.18	6.18	6	6	6.33	6.33	7.4	7.4	6.72	6.72	7.78	7.78	7.34	7.34	14.2	12.6	9.29	9.29	41.6	41.6	9.65	9.65	20.6	7.77	9.86	8.34	6.76	6.14	3.73	2.92	2.89	2.89	2.37	2.37	2.38	2.38	1.86	1.49	2.07	1.42	1.41	1.47	1.41
Receivables Turnover	4.33	4.33	4.57	4.57	-	2.99	-	4.55	-	3.91	7.52 K	3.75	5.68 K	2.85	-	3.5	-	4.19	-	3.65	-	3.91	-	4.01	-	2.96	-	-	-	1.68 K	-	2.6	-	-	-	3.37 K	-	2.94	4.9 K	4.9 K	-	-	1.83	-	-	-	-
Payables Turnover	3.32	3.32	2.23	2.23	0.56	2.5	1.98	3.9	0.868	1.77	4.29 K	3.34	4.5 K	1.23	4.15 K	4.56	4.58 K	1.03	3.1 K	1.52	0.537	0.537	0.215	0.327	0.419	0.504	0.549	0.221	0.309	0.479	0.227	0.724	0.82	0.704	1.89	2.37	2.21	4.42	6.34	6.34	0.97	0.286	2.24	0.07	-	0.235	-
Inventory Turn Over	0.369	0.369	0.526	0.526	0.376	0.376	0.59	0.59	0.424	0.424	1.79 K	0.488	1.59 K	0.437	1.73 K	0.691	1.77 K	0.123	1.48 K	0.361	0.256	0.256	0.189	0.189	0.339	0.339	0.322	0.173	0.454	0.634	0.309	0.529	0.686	-	0.7	0.7	0.434	0.434	0.494	0.494	1.21	5.88	0.891	0.844	-	2.62	-
Fixed Asset Turnover	1.01	1.01	1.18	1.18	1.03	1.03	1.1	1.1	0.952	0.952	2.19 K	1.09	1.82 K	0.91	1.69 K	0.955	1.77 K	0.636	1.19 K	0.594	0.484	0.484	0.635	0.635	0.546	0.546	0.503	0.444	395	730	0.686	0.913	1.17	1.03	823	823	0.758	0.758	838	838	1.06	1	0.869	0.99	-	1.23	-
Asset Turnover	0.149	0.149	0.147	0.147	0.132	0.132	0.151	0.151	0.149	0.149	359	0.18	371	0.186	368	0.209	398	0.143	324	0.161	0.135	0.135	0.156	0.156	0.131	0.131	0.135	0.12	104	103	0.101	0.084	0.145	0.115	95.4	95.4	0.09	0.09	115	115	0.105	0.088	0.14	0.091	-	0.111	-
Operating Cash Flow Sales Ratio	0.152	0.152	0.512	0.512	0.084	0.084	0.28	0.28	0.091	0.091	0.319	0.364	0.067	0.096	-	0.196	-	-0.154	-	0.339	0.079	0.079	-0.174	-0.174	0.275	0.275	0.285	-0.103	-0.0	-0.0	1.34	-1.01	0.016	-0.253	0.0	0.0	-0.296	-0.296	-0.0	-	0.381	-	0.074	-	-	-	-
Free Cash Flow Operating Cash Flow Ratio	0.481	0.481	0.637	0.637	-0.249	-0.249	0.777	0.777	-1.06	-1.06	0.281	0.562	-0.442	-0.004	-	0.703	-	1.7	-	-0.084	0.735	0.735	0.093	0.093	-0.127	-0.127	0.598	4.94	7.55	1.56	0.637	1.08	-3.98	1	0.747	0.747	1.15	1.15	1.84	-	0.859	-	2.22	-	-	-	-
Cash Flow Coverage Ratios	0.072	0.072	0.243	0.243	0.032	0.032	0.104	0.104	0.038	0.038	323	0.184	77.8	0.056	-	0.127	-	-0.067	-	0.18	0.029	0.029	-0.082	-0.082	0.1	0.1	0.098	-0.031	-0.046	-0.062	0.407	-0.213	0.024	-0.204	0.216	0.216	-0.192	-0.192	-0.142	-	0.247	-	0.058	-	-	-	-
Short Term Coverage Ratios	0.328	0.328	0.867	0.867	0.307	0.307	0.807	0.807	-	-	985 K	563	251	0.18	-	0.347	-	-0.206	-	0.552	0.427	0.427	-0.603	-0.603	0.626	0.626	0.828	-0.304	-0.493	-0.597	3.63	-1.05	0.03	-0.244	0.275	0.275	-0.246	-0.246	-0.143	-	0.311	-	0.083	-	-	-	-
Capital Expenditure Coverage Ratio	1.93	1.93	2.75	2.75	0.801	0.801	4.49	4.49	0.486	0.486	1.39	2.28	0.693	0.996	-	3.37	-	-1.43	-	0.922	3.78	3.78	-1.1	-1.1	0.887	0.887	2.49	-0.254	-0.153	-1.77	2.75	-12.2	0.201	-	3.96	3.96	-6.64	-6.64	-1.2	-	7.08	-	0.818	-	-	-	-
Dividend Paid And Capex Coverage Ratio	1.93	1.93	2.75	2.75	0.801	0.801	4.49	4.49	0.486	0.486	1.39	2.28	0.693	0.996	-	3.37	-	-1.43	-	0.922	3.78	3.78	-1.1	-1.1	0.887	0.887	2.49	-0.254	-0.153	-1.77	2.75	-12.2	0.201	-	3.96	3.96	-6.64	-6.64	-1.2	-	7.08	-	0.818	-	-	-	-
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Price To Free Cash Flows Ratio, P/FCF	210 K	210 K	47.7 K	47.7 K	-877 K	-877 K	102 K	102 K	-266 K	-307 K	151	122 K	-170	-26.6 M	-	59 K	-	-14.8 K	-	-173 K	60.2 K	62.1 K	-210 K	-243 K	-139 K	-133 K	35.6	-15.3	-6 K	-25.3 K	15.1	-15.3	-	-84.1	42.3 K	41.5 K	-27.1 K	-27 K	-32 K	-	37.4 K	-	87.1 K	-	-	-	-
Price To Operating Cash Flows Ratio, P/OCF	101 K	101 K	30.4 K	30.4 K	218 K	218 K	79.2 K	79.2 K	281 K	325 K	42.4	68.8 K	75.1	105 K	-	41.5 K	-	-25.1 K	-	14.6 K	44.2 K	45.7 K	-19.5 K	-22.6 K	17.7 K	16.9 K	21.3	-75.8	-45.3 K	-39.5 K	9.6	-16.5	-	-84.1	31.6 K	31 K	-31.2 K	-31 K	-58.7 K	-	32.1 K	-	194 K	-	-	-	-
Price Cash Flow Ratio, P/CF	101 K	101 K	30.4 K	30.4 K	218 K	218 K	79.2 K	79.2 K	281 K	325 K	42.4	68.8 K	75.1	105 K	-	41.5 K	-	-25.1 K	-	14.6 K	44.2 K	45.7 K	-19.5 K	-22.6 K	17.7 K	16.9 K	21.3	-75.8	-45.3 K	-39.5 K	9.6	-16.5	-	-84.1	31.6 K	31 K	-31.2 K	-31 K	-58.7 K	-	32.1 K	-	194 K	-	-	-	-
Enterprise Value Multiple, EV	59.4 K	59.4 K	60.4 K	60.4 K	85 K	85 K	207 K	207 K	165 K	191 K	117	161 K	34.8	61.1 K	63.9	57.9 K	52	10.8 K	0.017	17.3 K	14.1 K	14.6 K	9.56 K	11 K	66.3 K	63.2 K	-21.1	39.6	-49.2 K	-39.4 K	415	-29.9	-0.884	-448	-24.4 K	-23.9 K	-194 K	-193 K	-72 K	-80 K	-1.11 M	16.5	173 K	159 K	-	37.1	-
Price Fair Value, P/FV	13.2 K	13.2 K	11.6 K	11.6 K	15 K	15 K	20.1 K	20.1 K	24.1 K	27.8 K	35.9 K	33.3 K	12.5 K	12.6 K	14.3 K	13.2 K	8.7 K	4.05 K	9.87	10 K	4.37 K	4.52 K	22.1 K	25.5 K	6.13 K	5.84 K	16.8	7.31	8.22 K	8.06 K	8.8	8.57	-	7.1	2.72 K	2.67 K	1.97 K	1.96 K	2.43 K	2.7 K	2.38 K	1.43	4.15 K	1.7 K	-	1.41	-

Alle Zahlen in RUB-Währung

Multiplikatoren sind ein wichtiges Instrument der Finanzanalyse für das Unternehmen Институт стволовых клеток человека, das es Investoren und Analysten ermöglicht, den Unternehmenswert und die Investitionsattraktivität schnell anhand des Verhältnisses von Marktindikatoren zu den finanziellen Ergebnissen des Unternehmens zu bewerten. Im Wesentlichen drücken Multiplikatoren aus, wie der Markt das Unternehmen im Verhältnis zu seinem Gewinn, Umsatz, Eigenkapital oder anderen wichtigen Kennzahlen bewertet.

Vorteile der Verwendung von Finanzkennzahlen

Vereinfachte Datenanalyse
Finanzkennzahlen verwandeln große Mengen an Buchhaltungsdaten in kompakte und leicht interpretierbare Indikatoren, was die Beurteilung des Unternehmenszustands erheblich vereinfacht.
Vergleichbarkeit zwischen Unternehmen
Multiplikatoren standardisieren Finanzkennzahlen und ermöglichen so einen objektiven Vergleich von Unternehmen unterschiedlicher Größe, Branche und Marktkapitalisierung.
Erkennung von Trends und Problemen
Die regelmäßige Analyse von Kennzahlen hilft, die Entwicklung der finanziellen Gesundheit zu verfolgen, Stärken und Schwächen des Geschäfts sowie potenzielle Risiken zu identifizieren.
Entscheidungsunterstützung
Finanzielle Multiplikatoren dienen Investoren, Gläubigern und der Unternehmensführung als wichtiges Instrument bei Investitions-, Kredit- und Managemententscheidungen.
Beschleunigte Bewertung der Investitionsattraktivität
Mit Hilfe von Kennzahlen können schnell wichtige Leistungs-, Liquiditäts- und Finanzstabilitätsindikatoren bestimmt werden, was eine zügige Bewertung der Attraktivität von Unternehmen für Investitionen ermöglicht.

Die Verwendung von Multiplikatoren ermöglicht den Vergleich von Unternehmen, auch wenn sie sich in Größe oder Branche unterscheiden, da sie Finanzdaten in für die Analyse geeignete Kennzahlen standardisieren. Dies ist besonders nützlich zur Bewertung von Unternehmen, bei denen eine direkte Analyse der Finanzberichte komplex sein kann oder tiefgehendes Fachwissen erfordert.

Finanzkennzahlen anderer Aktien in der Pharmaeinzelhändler

Name	Preis	% 24h	Marktkapitalisierung	Land
MorphoSys AG MOR	-	2.43 %	$ 254 M	Germany
Arbutus Biopharma Corporation ABUS	$ 4.79	2.35 %	$ 795 M	Canada
Aeglea BioTherapeutics AGLE	-	-	$ 1.01 B	USA
Aclaris Therapeutics ACRS	$ 3.04	4.83 %	$ 235 M	USA
Alpine Immune Sciences ALPN	-	-	$ 2.17 B	USA
AlloVir ALVR	-	4.14 %	$ 49.1 M	USA
Ampio Pharmaceuticals AMPE	-	-11.43 %	$ 502 K	USA
Applied Molecular Transport AMTI	-	-	$ 10.1 M	USA
Aptorum Group Limited APM	$ 1.17	4.46 %	$ 6.38 M	China
Aptevo Therapeutics APVO	$ 0.93	-8.81 %	$ 257 K	USA
Athersys ATHX	-	3.77 %	$ 22.4 M	USA
Alexion Pharmaceuticals, Inc. ALXN	-	-	$ 40.3 B	USA
Avenue Therapeutics ATXI	-	-52.27 %	$ 4.45 M	USA
AVROBIO AVRO	-	1083.1 %	$ 745 M	USA
BioDelivery Sciences International BDSI	-	-4.8 %	$ 255 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	-	-1.52 %	$ 24.7 M	USA
BeiGene, Ltd. BGNE	-	0.49 %	$ 251 B	Cayman-islands
Midatech Pharma plc MTP	-	-18.52 %	$ 27.3 M	Britain
Bellicum Pharmaceuticals BLCM	-	-9.72 %	$ 5.89 M	USA
Berkeley Lights BLI	-	-7.31 %	$ 87 M	USA
bluebird bio BLUE	-	-	$ 546 M	USA
Ascendis Pharma A/S ASND	$ 212.81	1.71 %	$ 5 B	Danmark
Calithera Biosciences CALA	-	-10.95 %	$ 876 K	USA
Cerevel Therapeutics Holdings CERE	-	-	$ 7.29 B	USA
Alterity Therapeutics Limited ATHE	$ 3.1	0.16 %	$ 7.46 B	Australia
Biophytis SA BPTS	-	-13.47 %	$ 169 M	France
ARCA biopharma ABIO	-	1052.0 %	$ 415 M	USA
Acasti Pharma ACST	-	4.01 %	$ 150 M	Canada
Adaptimmune Therapeutics plc ADAP	-	-15.15 %	$ 60.3 M	Britain
Celsion Corporation CLSN	-	-6.63 %	$ 13.9 M	USA
BioVie BIVI	$ 1.27	-3.05 %	$ 1.88 M	USA
Albireo Pharma ALBO	-	-0.23 %	$ 916 M	USA
BioNTech SE BNTX	$ 95.03	0.95 %	$ 27.2 B	Germany
Amphastar Pharmaceuticals AMPH	$ 26.81	1.36 %	$ 1.3 B	USA
Anika Therapeutics ANIK	$ 9.48	0.96 %	$ 139 M	USA
Cortexyme CRTX	-	-1.05 %	$ 67.1 M	USA
Can-Fite BioPharma Ltd. CANF	$ 0.18	-25.03 %	$ 392 M	Israel
CTI BioPharma Corp. CTIC	-	-	$ 1.2 B	USA
Arena Pharmaceuticals ARNA	-	-6.81 %	$ 3.04 B	USA
Catalyst Biosciences CBIO	$ 12.37	2.06 %	$ 814 M	USA
Acer Therapeutics ACER	-	2.71 %	$ 14 M	USA
Axon Enterprise AXON	$ 591.15	0.02 %	$ 44.8 B	USA
Ayala Pharmaceuticals AYLA	-	-	$ 7.46 M	Israel
Aytu BioScience AYTU	$ 2.53	-0.39 %	$ 15.9 M	USA
AstraZeneca PLC AZN	$ 92.45	0.34 %	$ 96.9 B	Britain
Celldex Therapeutics CLDX	$ 26.83	0.94 %	$ 1.73 M	USA
Acorda Therapeutics ACOR	-	-24.86 %	$ 820 K	USA
Brickell Biotech BBI	-	-5.38 %	$ 6.06 M	USA
Burford Capital Limited BUR	$ 9.0	-1.32 %	$ 1.48 B	Britain

Институт стволовых клеток человека Kennzahlen 2006-2025 | ISKJ

Kennzahlen Jährlich Институт стволовых клеток человека

Price Earnings Ratio, P/E

Price Sales Ratio, P/S

Price To Book Ratio, P/B

Price Earnings To Growth Ratio, PEG

Operating Cash Flow Per Share

Free Cash Flow Per Share

Cash Per Share

Payout Ratio

Dividend Yield

Current Ratio

Quick Ratio

Cash Ratio

Days Of Sales Outstanding, DSO

Days Of Inventory Outstanding, DIO

Days Of Payables Outstanding, DPO

Operating Cycle

Cash Conversion Cycle

Gross Profit Margin

Operating Profit Margin

Pretax Profit Margin

Net Profit Margin

Effective Tax Rate

Return On Assets, ROA

Return On Equity, ROE

Return On Capital Employed, ROCE

Net Income Per Ebt

Ebt Per Ebit

Ebit Per Revenue

Debt Ratio

Debt Equity Ratio

Long Term Debt To Capitalization

Total Debt To Capitalization

Interest Coverage

Cash Flow To Debt Ratio

Company Equity Multiplier

Receivables Turnover

Payables Turnover

Inventory Turn Over

Fixed Asset Turnover

Asset Turnover

Operating Cash Flow Sales Ratio

Free Cash Flow Operating Cash Flow Ratio

Cash Flow Coverage Ratios

Short Term Coverage Ratios

Capital Expenditure Coverage Ratio

Dividend Paid And Capex Coverage Ratio

Dividend Payout Ratio

Price To Free Cash Flows Ratio, P/FCF

Price To Operating Cash Flows Ratio, P/OCF

Price Cash Flow Ratio, P/CF

Enterprise Value Multiple, EV

Price Fair Value, P/FV